Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Properties of Insulin Icodec in Children and Adolescents With Type 2 Diabetes
NCT05790681Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2023
- Primary completion
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of insulin icodec in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoints: Area under the serum insulin icodec concentration-time curve after a single dose, Maximum observed serum insulin icodec concentration after a single dose and 1 more. Started Apr 2023; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05790681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05790681.